L
Lucy S. Vilas Boas
Researcher at University of São Paulo
Publications - 24
Citations - 825
Lucy S. Vilas Boas is an academic researcher from University of São Paulo. The author has contributed to research in topics: Vaccination & Congenital cytomegalovirus infection. The author has an hindex of 13, co-authored 22 publications receiving 763 citations.
Papers
More filters
Journal ArticleDOI
Dengue and Dengue Hemorrhagic Fever among Adults: Clinical Outcomes Related to Viremia, Serotypes, and Antibody Response
Adriana Oliveira Guilarde,Marília Dalva Turchi,João Bosco Siqueira,Valéria Christina de Rezende Féres,Benigno Alberto Moraes da Rocha,José Eduardo Levi,Vanda Akico Ueda Fick de Souza,Lucy S. Vilas Boas,Cláudio Sérgio Pannuti,Celina Maria Turchi Martelli +9 more
TL;DR: Viremia was detected after defervescence in adult patients classified as having DHF or intermediate DF/DHF, and secondary infection was not a predictor of severe clinical manifestation in adults with infected with the DV3 serotype.
Journal ArticleDOI
The benefit of influenza vaccination after bone marrow transplantation
Clarisse Martins Machado,Maria Regina Alves Cardoso,I. F. da Rocha,Lucy S. Vilas Boas,Frederico Luiz Dulley,Cláudio Sérgio Pannuti +5 more
TL;DR: It is concluded that influenza vaccination plays an important role in protecting BMT recipients against influenza and all efforts should be made to ensure good compliance with vaccination.
Journal ArticleDOI
Use of Oseltamivir to control influenza complications after bone marrow transplantation.
Clarisse Martins Machado,Lucy S. Vilas Boas,A. V. A. Mendes,I. F. da Rocha,D Sturaro,Frederico Luiz Dulley,Cláudio Sérgio Pannuti +6 more
TL;DR: Oseltamivir proved to be safe and appears to have played an important role in the outcome of influenza infection in this population of bone marrow transplant recipients, and the therapeutic and/or prophylactic benefits of OseltAMivir in BMT recipients remain to be demonstrated.
Journal ArticleDOI
CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy.
Clarisse Martins Machado,Frederico Luiz Dulley,Lucy S. Vilas Boas,Jussara Bianchi Castelli,M. C. M. A. Macedo,Roberto Luiz da Silva,R Pallota,Rosaura Saboya,Cláudio Sérgio Pannuti +8 more
TL;DR: The median time for occurrence of CMV-IP was delayed during PE strategy and the cost-effectiveness ofCMV surveillance after day +100 should be investigated in this population.
Journal ArticleDOI
Serum levels of proinflammatory cytokines in painful knee osteoarthritis and sensitization.
Marta Imamura,Fernando Ezquerro,Fábio Marcon Alfieri,Lucy S. Vilas Boas,Tania Regina Tozetto-Mendoza,J. Chen,Levent Özçakar,Lars Arendt-Nielsen,Linamara Rizzo Battistella +8 more
TL;DR: The objective of this study was to investigate the seric concentration of pro and anti-inflammatory cytokines in patients with painful knee osteoarthritis and to correlate the levels of these biomarkers with the patients' functional capacity and pressure pain threshold values.